What is the next step for a patient with elevated Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) levels, but no abdominal pain and otherwise unremarkable Comprehensive Metabolic Panel (CMP) lab work?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 3, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

The next step for a patient with elevated liver enzymes (AST 58 and ALT 114) without abdominal pain would be to repeat the liver function tests in 2-4 weeks to determine if these abnormalities persist, as recommended by the most recent guidelines 1. This approach is supported by the fact that mild elevations in liver enzymes can be transient and may not necessarily indicate a serious underlying condition.

  • A comprehensive hepatic panel, including alkaline phosphatase, bilirubin, albumin, and prothrombin time, should be ordered to assess liver function more thoroughly 1.
  • A thorough history should be obtained regarding alcohol use, medications (including over-the-counter drugs and supplements), recent illnesses, and family history of liver disease, as these factors can contribute to elevated liver enzymes 1.
  • If the elevated enzymes persist on repeat testing, further evaluation with hepatitis serology (hepatitis A, B, and C), iron studies, autoimmune markers (ANA, anti-smooth muscle antibody), and an ultrasound of the liver would be appropriate, as suggested by the American College of Radiology 1. The mild elevation of transaminases with ALT higher than AST suggests a hepatocellular pattern of injury rather than cholestatic or infiltrative disease, which is commonly seen in viral hepatitis, medication-induced liver injury, and early stages of fatty liver disease 1. According to the AGA clinical practice update on the role of noninvasive biomarkers in the evaluation and management of nonalcoholic fatty liver disease, patients with clinical suspicion of NAFLD should undergo further evaluation, including screening and/or serologic evaluation for alternate causes of chronic hepatitis 1. The patient's liver enzymes should be monitored, and lifestyle modifications should be recommended to prevent progression of potential liver disease, as suggested by the most recent guidelines 1.

From the Research

Laboratory Results

  • AST: 58
  • ALT: 114
  • Other lab work: unremarkable
  • No abdominal pain

Possible Next Steps

  • Further evaluation to determine the cause of elevated liver enzymes, as the current lab work is unremarkable and there is no abdominal pain 2
  • Consider imaging studies, such as ultrasound, to rule out other possible causes of chronic liver disease and to detect any potential complications 3, 4
  • Sequential measurement of relevant autoantibodies and liver histology may be necessary to facilitate diagnosis 2
  • Immunosuppressive therapy may be considered if autoimmune hepatitis is suspected, as it has been shown to prevent or stop the development of cirrhosis and improve prognosis 2, 5

Treatment Options

  • Ursodeoxycholic acid (UDCA) may be considered as a treatment option, as it has been shown to slow disease progression in primary biliary cirrhosis and reduce serum liver enzymes in patients with chronic hepatitis 2, 6

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

[Autoimmune liver disease: diagnosis and therapy].

Zeitschrift fur Gastroenterologie, 2004

Research

Ultrasound findings in autoimmune hepatitis.

World journal of gastroenterology, 2018

Research

Imaging of autoimmune hepatitis and overlap syndromes.

Abdominal radiology (New York), 2017

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.